Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00986310 · ClinicalTrials.gov registry record · NA
Efficacy of Fluoxetine in Reducing Ictal Hypoventilation in Patients With Partial Epilepsy
A NA study of Uncontrolled Partial Epilepsy and Ictal Hypoventilation, sponsored by University of California, Davis.
- Completed
- Registry status
- NA
- Development phase
- 2
- Enrollment target
- 1
- Study location
NCT00986310: Completed NA study of Uncontrolled Partial Epilepsy and Ictal Hypoventilation, sponsored by University of California, Davis.
NCT00986310 is a NA study of Uncontrolled Partial Epilepsy and Ictal Hypoventilation that has completed, run by University of California, Davis. The registered enrollment target is 2 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00986310, a NA study of Uncontrolled Partial Epilepsy and Ictal Hypoventilation, has completed, sponsored by University of California, Davis.
- COMPLETED
- Registry status
- NA
- Development phase
- 2 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the effects of fluoxetine on breathing mechanisms during seizures. Patients with partial epilepsy commonly have changes in their breathing mechanisms during seizures. These changes may increase the risk of serious side effects from seizures, including sudden unexplained death in epilepsy (SUDEP), which affects 2-10 per 1000 patients with epilepsy each year. Fluoxetine (Prozac) may help to stimulate breathing through its actions in the brain and has been shown to improve breathing changes seen with seizures in certain animals. Fluoxetine is in a class of medications called selective serotonin reuptake inhibitors (SSRIs). It works by increasing the amount of serotonin, a natural substance in the brain, at synapses, the junctions at which nerve cells in the brain communicate. Fluoxetine is currently approved by the United States Food and Drug Administration (FDA) for the treatment of patients with Major Depressive Disorder, Obsessive Compulsive Disorder, Bulimia Nervosa, Panic Disorder and Premenstrual Dysphoric Disorder.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Fluoxetine
Study Locations (1)
California
- University of California, Davis - Sacramento
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2009-08 |
| Est. Completion | 2012-06 |
| Phase | NA |
What the finished NCT00986310 record still lists
NCT00986310 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with Uncontrolled Partial Epilepsy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00986310 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00986310 about?
NCT00986310 is a clinical study titled "Efficacy of Fluoxetine in Reducing Ictal Hypoventilation in Patients With Partial Epilepsy". The purpose of this study is to determine the effects of fluoxetine on breathing mechanisms during seizures. Patients with partial epilepsy commonly have changes in their breathing mechanisms during seizures. These changes may increase the risk of serious side effects from seizures, including sudden...
What is the current status of trial NCT00986310?
This trial is currently completed. It is a NA study. The enrollment target is 2 participants. The study started on 2009-08. Estimated completion is 2012-06.
What conditions does trial NCT00986310 study?
This clinical trial studies the following conditions: Uncontrolled Partial Epilepsy, Ictal Hypoventilation.
What interventions are being tested in trial NCT00986310?
The interventions under investigation include: Placebo (DRUG), Fluoxetine (DRUG).
Who is sponsoring clinical trial NCT00986310?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00986310 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00986310's enrollment target sits among peer trials
2 1997th of 2000 the lowest of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia